New York Fashion Week 2025-26, redefining luxury, creativity, and venue storytelling

New York — At New York Fashion Week 2025, Coach unveiled a groundbreaking...

Ralph Lauren unveils Spring 2026 collection at New York Fashion Week with timeless luxury

Ralph Lauren launched New York Fashion Week with an intimate studio show that...

Gun violence and domestic terrorism in the US – Experts call for safety

The Minneapolis Catholic school shooting has thrust gun violence and domestic terrorism back...

Nevada’s two-day shutdown shows how fragile state cyber defenses still are

The Nevada cyberattack, a Nevada ransomware attack detected on Sunday, August 24, forced...

Coronavirus vaccines on the market in September?

The British pharmaceutical company AstraZeneca expects to be able to market two billion doses of the vaccine to the coronavirus in September if ongoing research reports positive results from the company’s CEO.

The company is partnering with the University of Oxford, which has led clinical trials on the drug. It is already in production but the approval of the Agency is pending before it is placed on the market. Research is expected to be completed in the coming months.

So far we are on the right track and production is about to begin, but we must be ready for it as soon as results are available, says AstraZeneca CEO Pascal Soriot in an interview with the BBC .

He says that in August or September it will be available whether the vaccine is active or not.

The company announced earlier this week that it has reached an agreement with the Gavi Vaccination Alliance, CEPI (Coalition for Epidemic Preparedness Innovation), a corporate and government partner for anti-epidemic preparedness and the Serum Institute of India to double its production capacity of COV 19 – the vaccine – in two billion doses.

The agreement with Serum, one of the world’s largest vaccine manufacturers, will ensure that sufficient supplies are available for the world’s poorest countries.

AstraZeneca is already collaborating on the vaccine production for Europe and the United States and is currently preparing for production in China as well as in India.

Pascal Soriot says AstraZeneca, which performs this job without a profit in mind, could lose high sums in the experiment if clinical trials indicate that the drug is not effective in the COVID-19 battle. Financial risks are spread by organizations such as CEPI.

The University of Oxford began researching the vaccine with the help of hundreds of volunteers in April and will now be expanded to 10,000 participants.

More

Show your support if you like our work.

Author

Amanda Graham
Amanda Graham
News staff at The Eastern Herald. Writing and publishing news on the economy, politics, business, and current affairs from around the world.

Comments

Editor's Picks

Trending Stories

Discover more from The Eastern Herald

Subscribe now to keep reading and get access to the full archive.

Continue reading